Spotlight Therapeutics, Inc., whose president and CEO is Mary Haak-Frendscho, closes its Series A round. The Hayward, Calif. biotech company raised $30 million in a round led by GV. Established in 2018, Spotlight is developing non-viral gene editing therapeutics for direct in vivo editing of target genes. The company’s approach is designed to avoid the complexity and toxicities associated with current cell, viral and nanoparticle delivery methods. Spotlight is advancing lead programs in hemoglobinopathies and immuno-oncology. Prior to Spotlight, Mary was a venture partner with Versant Ventures and CEO of Blueline Bioscience, Versant’s vehicle for new company creation in Canada. Her background also includes establishing and chairing Compugen, Inc., being CEO of Igenica Biotherapeutics, and founding president and chief scientific officer of Takeda San Francisco. https://www.spotlighttx.com/.